Tumor-associated antigens on tumor membrane vesicles (TAA-TMV) (TAA-TMV)

Tumor-associated antigens (TAAs) on tumor membrane vesicles (TMVs) represent a complex therapeutic target and a potent platform for cancer immunotherapy. TMVs, which include exosomes and microvesicles, are small membrane-bound particles secreted by cancer cells that carry a molecular "fingerprint" of the parent tumor, including proteins, lipids, and nucleic acids (Whiteside, 2016, AAPS Journal). These vesicles play a dual role in cancer biology: they can facilitate tumor progression by modulating the microenvironment and suppressing immune cells, but they also serve as a rich source of antigens for the immune system (Wolfers et al., 2001, Nature Medicine). In a therapeutic context, TMVs are isolated and used as vaccines to deliver a broad spectrum of TAAs to dendritic cells, which then process and present these antigens to T cells to initiate a systemic anti-tumor response (Cocks et al., 2021, Journal of Extracellular Vesicles). This multi-antigen approach is designed to overcome the challenge of tumor heterogeneity and antigen loss that often leads to resistance in single-antigen therapies. However, the clinical application of TMVs faces challenges, such as the need to remove immunosuppressive components like PD-L1 or TGF-beta that may be present on the vesicle surface (Chen et al., 2018, Nature).

Other names

Tumor-derived extracellular vesiclesTumor-derived exosomesCancer-derived vesiclesTumor-derived microvesiclesTEXs

Stimulation of the adaptive immune system through the presentation of a diverse array of tumor-specific and tumor-associated antigens to dendritic cells, leading to the activation and proliferation of cytotoxic T lymphocytes (CTLs) and helper T cells.